Description of the drug Arimidex coated tablets Feature: Composition 1 tablet film coating contains: Surfactant: 1.0 mg anastrozole Other ingredients: lactose monohydrate 93.0 mg, 2.0 mg povidone, sodium carboxymethyl starch 3.0 mg Magnesium stearate 1.0 mg the composition of film coating: hypromellose 1.50 mg, 0.30 mg of macrogol 300, titanium dioxide 0.45 mg Farmgruppa: antitumor agent - estrogen synthesis inhibitor. Farmdeystvie: ARIMIDEX is a highly non-steroidal aromatase inhibitor - an enzyme, whereby in postmenopausal women androstenedione in peripheral tissues converted into estrone and then to estradiol. Reduced levels of circulating estradiol in breast cancer patients has a therapeutic effect. In postmenopausal women, Arimidex ® at a daily dose of 1 mg of estradiol is reduced by 80%. ARIMIDEX has no progestogenic, androgenic and estrogenic activity. ARIMIDEX at daily doses up to 10 mg had no effect on the secretion of cortisol and aldosterone, therefore, for application of the drug is required ARIMIDEX substitutive corticosteroids. Effect on bone mineral density It is shown that in patients with gormonopozitivnym early breast cancer in postmenopausal women who take Arimidex , changes in bone can be prevented in accordance with the standards established for the treatment of patients with certain risk of fractures. Thus, the advantage of the drug Arimidex in combination with bisphosphonates (compared to drug therapy alone Arimidex ) in patients with moderate and high risk of fractures has been demonstrated after 12 months in terms of bone mineral density, structural changes in bone tissue and markers of bone resorption. Moreover, in the low-risk group was no change indicator bone mineral density during therapy with a drug Arimidex and supportive treatment with vitamin D and calcium.